Damaging missense variants in implicate a role for IGF-1 resistance in the etiology of type 2 diabetes.
Cell genomics 2022 ; 2: None.
Gardner EJ, Kentistou KA, Stankovic S, Lockhart S, Wheeler E, Day FR, Kerrison ND, Wareham NJ, Langenberg C, O'Rahilly S, Ong KK, Perry JRB
DOI : 10.1016/j.xgen.2022.100208
PubMed ID : 36530175
PMCID : PMC9750938
URL : https://linkinghub.elsevier.com/retrieve/pii/S2666979X22001616
Abstract
Type 2 diabetes (T2D) is a heritable metabolic disorder. While population studies have identified hundreds of common genetic variants associated with T2D, the role of rare (frequency < 0.1%) protein-coding variation is less clear. We performed exome sequence analysis in 418,436 (n = 32,374 T2D cases) individuals in the UK Biobank. We identified previously reported genes (, , ) in addition to missense variants in (n = 31 carriers; odds ratio [OR] = 5.5 [95% confidence interval = 2.5-12.0]; p = 6.4 × 10), (n = 245; OR = 2.3 [1.6-3.2]; p = 3.2 × 10), and (n = 394; OR = 2.4 [1.8-3.2]; p = 1.3 × 10). Carriers of damaging missense variants within were also shorter (-2.2 cm [-1.8 to -2.7]; p = 1.2 × 10) and had higher circulating insulin-like growth factor-1 (IGF-1) protein levels (2.3 nmol/L [1.7-2.9]; p = 2.8 × 10), indicating relative IGF-1 resistance. A likely causal role of IGF-1 resistance was supported by Mendelian randomization analyses using common variants. These results increase understanding of the genetic architecture of T2D and highlight the growth hormone/IGF-1 axis as a potential therapeutic target.